Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of some unusual options trading activity on Thursday. Investors acquired 12,642 call options on the company. This represents an increase of 1,139% compared to the typical daily volume of 1,020 call options.

In related news, insider Jay Barth sold 30,000 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $10.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider now directly owns 64,184 shares of the company’s stock, valued at approximately $641,840. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Hung Do sold 29,914 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $8.00, for a total value of $239,312.00. Following the sale, the insider now directly owns 474,438 shares of the company’s stock, valued at $3,795,504. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Amicus Therapeutics by 4.2% in the first quarter. Vanguard Group Inc. now owns 8,687,760 shares of the biopharmaceutical company’s stock valued at $61,944,000 after buying an additional 353,949 shares in the last quarter. Palo Alto Investors LLC increased its stake in Amicus Therapeutics by 23.0% in the first quarter. Palo Alto Investors LLC now owns 7,882,988 shares of the biopharmaceutical company’s stock valued at $56,206,000 after buying an additional 1,472,958 shares in the last quarter. Janus Capital Management LLC increased its stake in Amicus Therapeutics by 3.6% in the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock valued at $50,883,000 after buying an additional 244,906 shares in the last quarter. Morgan Stanley increased its stake in Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after buying an additional 3,055,039 shares in the last quarter. Finally, State Street Corp increased its stake in Amicus Therapeutics by 0.9% in the first quarter. State Street Corp now owns 5,766,929 shares of the biopharmaceutical company’s stock valued at $41,118,000 after buying an additional 50,982 shares in the last quarter.

A number of analysts recently issued reports on the company. Robert W. Baird reissued an “outperform” rating and set a $12.00 target price on shares of Amicus Therapeutics in a research note on Friday, June 30th. BidaskClub raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. ValuEngine raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. J P Morgan Chase & Co set a $13.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 5th. Finally, Chardan Capital reissued a “buy” rating and set a $12.50 target price on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $11.46.

Amicus Therapeutics (NASDAQ:FOLD) opened at 10.44 on Friday. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $10.73. The company’s market capitalization is $1.49 billion. The stock’s 50 day moving average is $8.63 and its 200 day moving average is $6.95.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. The firm had revenue of $4.20 million during the quarter, compared to analysts’ expectations of $4.16 million. The firm’s quarterly revenue was up 50.0% on a year-over-year basis. Analysts predict that Amicus Therapeutics will post ($1.45) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/07/09/amicus-therapeutics-target-of-unusually-high-options-trading-nasdaqfold.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.